Correction to: Nature https://doi.org/10.1038/s41586-023-05707-3 Published online 22 February 2023
In the version of this article initially published, the Fig. 1 timeline was missing an entry for 2009: “CD19.BB.z-CAR shows enhanced anti-leukemic efficacy and prolonged survival in mouse xenograft models of primary human B-ALL (Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009))”. In Box 1, the “Cytokines: IL-18” entry was missing two references : Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025–3033 (2017) and Svoboda, J. et al. Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy. Blood 140, 4612–4614 (2022). The errors have been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Labanieh, L., Mackall, C.L. Author Correction: CAR immune cells: design principles, resistance and the next generation. Nature 619, E26 (2023). https://doi.org/10.1038/s41586-023-06088-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-023-06088-3
- Springer Nature Limited